Please use this identifier to cite or link to this item:
http://hdl.handle.net/11434/813
Title: | Lessons and insights from ABO incompatible lung transplantation. |
Epworth Authors: | Cohney, Solomon (Shlomo) |
Other Authors: | Snell, Greg Holmes, M. Levvey, Bronwyn Shipp, A. Robertson, C. Westall, G. P. |
Keywords: | ABO Blood-Group System Blood Group Incompatibility Blood Group Incompatibility Fatal Outcome Graft Rejection Lung Transplantation ABO Blood-Group System Plasmapheresis Antithymocyte globulin Retransplantation Intravenous Immunoglobulin Oral Cyclophosphamide Sirolimus Fatal Thrombotic Microangiopathy Pretransplant Antibody Titers Antibody-mediated Overimmunosuppression UroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australia Department of Gastroenterology, Epworth HealthCare, Victoria, Australia |
Issue Date: | May-2013 |
Publisher: | Wiley Online |
Citation: | Am J Transplant. 2013 May;13(5):1350-3. |
Abstract: | With ABO blood group incompatibility (ABOi) between donor and recipient becoming a part of mainstream living-donor renal transplantation, the applicability of ABOi to other areas of transplantation is being reconsidered. Here we present a case of inadvertent ABOi lung retransplantation managed successfully with initial plasmapheresis, antithymocyte globulin and intravenous immunoglobulin; and subsequently with oral cyclophosphamide and sirolimus in addition to tacrolimus and prednisolone. Interestingly, in the setting of solid levels of tacrolimus and sirolimus, the patient developed a fatal thrombotic microangiopathy of uncertain origin subsequent to the cessation of cyclophosphamide at 9 years posttransplant. It is apparent that ABOi lung transplantation can result in surprisingly successful long-term outcomes. Low pretransplant antibody titers likely aid this and, in pediatric neonatal or infant cases, this may not be uncommon. We must proceed cautiously as there are significant risks. Understanding the monitoring, prevention and treatment of lung transplant antibody-mediated rejection, while avoiding the long-term complications of overimmunosuppression, will be the keys to the success of future cases. |
URI: | http://hdl.handle.net/11434/813 |
DOI: | 10.1111/ajt.12185 |
PubMed URL: | https://www.ncbi.nlm.nih.gov/pubmed/23465218 |
ISSN: | 1600-6143 1600-6135 |
Journal Title: | American Journal of Transplantation |
Type: | Journal Article |
Affiliated Organisations: | Department of Allergy, Immunology and Respiratory Medicine, Lung Transplant Service, Alfred Hospital and Monash University, Melbourne, Australia. |
Type of Clinical Study or Trial: | Case Reports |
Appears in Collections: | UroRenal, Vascular |
Files in This Item:
There are no files associated with this item.
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.